1. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants

   • Ken Ogasawara
   • Jeanelle Kam
   • Gopal Krishna

   Original Article 21 May 2021 Pages: 369 - 377

   

2. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation

   • Rachael Lawson
   • Lachlan Paterson
   • Stefanie Hennig

   Original Article 22 May 2021 Pages: 379 - 391

   

3. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers

   • Masanobu Takahashi
   • Yasuhiro Sakamoto
   • Chikashi Ishioka

   Original Article Open access 24 May 2021 Pages: 393 - 402

   

4. Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma

   • Yun Liu
   • Bo Zhang
   • Jing Huang

   Original Article 24 May 2021 Pages: 403 - 414

   

5. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis

   • Pawat Pattarawat
   • Jessica T. Hunt
   • Hwa-Chain Robert Wang

   Original Article 27 May 2021 Pages: 415 - 425

   

6. Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic–pharmacodynamic real-life study

   • Lauriane Goldwirt
   • B. Louveau
   • S. Mourah

   Original Article 31 May 2021 Pages: 427 - 437

   

7. Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients

   • Anna P. Sokolenko
   • Tatiana V. Gorodnova
   • Evgeny N. Imyanitov

   Original Article 02 June 2021 Pages: 439 - 450

   

8. Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors

   • Venkatesh Pilla Reddy
   • Adrian J. Fretland
   • Joseph A. Ware

   Original Article Open access 02 June 2021 Pages: 451 - 464

   

9. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers

   • Xiaoxue Zhu
   • Hongjie Qian
   • Xiaojiao Li

   Original Article Open access 04 June 2021 Pages: 465 - 474

   

10. Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability

    • Li Chen
    • Ciao-Sin Chen
    • Daniel L. Hertz

    Original Article 05 June 2021 Pages: 475 - 483

    

11. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment

    • Muhammad Wasif Saif
    • Carlos R. Becerra
    • Lee Rosen

    Original Article 07 June 2021 Pages: 485 - 497

    

12. Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

    • Bei Wang
    • Rong Deng
    • Whitney P. Kirschbrown

    Original Article Open access 09 June 2021 Pages: 499 - 512

    

13. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression

    • Kazuhisa Sugiu
    • Hiroshi Tazawa
    • Toshiyoshi Fujiwara

    Original Article 10 June 2021 Pages: 513 - 524

    

14. Serum and hematologic responses after three cycles of cabazitaxel therapy as predictors of survival in castration-resistant prostate cancer

    • Motohiro Fujiwara
    • Takeshi Yuasa
    • Junji Yonese

    Original Article 10 June 2021 Pages: 525 - 531

    

15. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients

    • Nuala Helsby
    • Minghan Yong
    • David Porter

    Original Article 10 June 2021 Pages: 533 - 542

    

16. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure

    • Ayako Tsuboya
    • Yutaro Kubota
    • Ken-ichi Fujita

    Original Article 11 June 2021 Pages: 543 - 553

    

17. Panobinostat penetrates the blood–brain barrier and achieves effective brain concentrations in a murine model

    • Morgan J. Homan
    • Andrea Franson
    • Bernard L. Marini

    Short Communication 11 June 2021 Pages: 555 - 562

    

18. Correction to: PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1

    • Shuo Yu
    • Yang Li
    • Lan Yang

    Correction 15 April 2021 Pages: 563 - 563